The mammalian Target of Rapamycin (mTOR)-mediated signaling transduction pathway has been observed to be deregulated in a wide variety of cancer and metabolic diseases. Despite extensive clinical development efforts, the well-known allosteric mTOR inhibitor rapamycin and structurally related rapalogs have failed to show signifi cant single-agent antitumor effi cacy in most types of cancer. This limited clinical success may be due to the inability of the rapalogs to maintain a complete blockade mTOR-mediated signaling. Therefore, numerous efforts have been initiated to develop ATP-competitive mTOR inhibitors that would block both mTORC1 and mTORC2 complex activity. Here, we describe our experimental approaches to develop Torin1 using a medium throughput cell-based screening assay and structure-guided drug design.
Introduction
signaling pathway that mediates growth and survival signals. Rapamycin, an allosteric inhibitor of mTOR that was originally identifi ed as an immunosuppressant and later as an anticancer agent, has greatly facilitated the study of mTOR signaling ( 2, 3 ) . As a key node in the oncogenic phosphoinositide 3-kinase signaling pathway, deregulation of the mTOR kinase has been often observed in human cancers (4) (5) (6) . Inspired by the promising in vitro anticancer effect, it is widely believed that rapamycin or related analogs (rapalogs) would be therapeutically effective by blocking the mTORC1's phosphorylation activity of S6K and 4EBPs, which are key upstream regulators of protein synthesis. However, extensive clinical evaluation has found rapamycin's in vivo effi cacy to be limited to a few rare cancers, such as renal cell carcinoma and mantle cell lymphoma ( 7 ) . This may be partially explained by the recent discovery that rapamycin could not block the function of mTORC1 completely and has little effect on mTORC2 complex in the majority of cell types ( 4, 8 ) . Moreover, the existence of a feedback loop that hyperactivates PI3K when mTORC1 is inhibited ( 9 ) and the recent discovery that rapamycin fails to completely inhibit mTORC1 indicates that ATP-competitive small molecule mTOR inhibitors might show broader effi cacy.
Structurally, the mTOR catalytic domain exhibits high sequence identity with PI3Ks and PI3K-related kinases (PIKK) such as ATR, ATM, DNA-PK, and SMG-1. The co-crystal structure of LY294002 with PI3K γ provides valuable insights that enable structure-guided design of numerous PI3K inhibitors ( 10 ) . The dual PI3K/mTOR inhibitor PI-103, similar to LY294002, which uses the morpholine oxygen as the hinge binding moiety, provides a molecular-entry point for the development of selective mTOR inhibitors ( 11, 12 ) . For example, PI-103 served as a "lead" compound for the structure-guided development of selective mTOR inhibitors such as KU-0063794 ( 13 ) and WYE-354 ( 14 ) and other related structures ( 15 ) using a rational designed approach (Fig. 1 ) . Preliminary biochemical analyses indicate that these compounds are, indeed, promising candidates for replacing rapamycin as future anticancer agents. Not only do these pharmacological inhibitors have enhanced effi cacy in suppressing hyperactive mTOR, but also they are highly 1. Immunodefi cient mice: NCR nude, nu/nu (Taconic Laboratories).
2. Drug vehicle: 20%:40%:40% (v/v) N -methyl-2-pyrrolidone: PEG400:water.
As illustrated in Fig. 2 , the workfl ow for developing potent and selective mTOR inhibitors commenced with a medium-throughput biochemical screening of a focused ATP-site directed heterocycle library. Compounds that exhibited activity in this assay were then profi led for selectivity across a panel of approximately 400 kinases using the Ambit KinomeScan methodology from which a class of quinoline-derived compounds appeared to exhibit the greatest selectivity for mTOR. Compounds were then evaluated for their ability to inhibit the downstream target of mTORC1 S6K T389 in a cellular assay utilizing mouse embryonic fi broblasts (MEFs). A key goal of this project was to identify compounds that exhibited selectivity for inhibition of mTOR relative to structurally homologous PIKK family members such as the PI3Ks. The ability of the compounds to inhibit PI3K was evaluated by measuring effects on the activation loop phosphorylation site of Akt T308 in the context of the S473D mutant form of Akt in PC-3 cells. The S473D mutant of Akt was employed because this "phospho-mimetic" mutation abolishes the effects that would result from mTORC2-mediated phosphorylation
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Overview of the Process
Medium through-put screening with mTORC1
Lead compounds of this site ( 8 ) . This is a necessary precaution because most inhibitors in our series are very potent inhibitors of mTORC2 and this would confound our ability to evaluate how potent they are as inhibitors of PI3K. The structure-activity relationships derived from these cellular assays was interpreted in the context of a molecular model for the presumed binding mode. A homology model of the threedimensional structure of mTOR was constructed using Autodock Vina. This information was then used to inform the design of iterative rounds of compound synthesis. Given the fairly challenging nature of the chemistry required to prepare these compounds, we were never able to prepare focused libraries of derivatives. The most potent and selective compounds were subjected to broader selectivity profi ling across a panel of approximately 450 kinases using the Ambit KinomeScan TM technology. The selected compounds chosen from this profi ling were then tested in Invitrogen SelectScreen ® lipid kinase panel including all of the PI3K isomers and DNA-PK. The most selective compounds were subject to metabolic stability studies using isolated mouse microsomes and then evaluated in mice for their pharmacokinetic and pharmacodynamic properties. Candidate compounds were then tested for antitumor effi cacy using mouse tumor xenograft models.
1. Combinatorial kinase-directed libraries were built from a variety of commercially available heterocycles using both solution and solid phase synthesis ( 16 ) . Simple and robust chemistries such as nucleophilic aromatic substitution and palladium-mediated couplings were used to install diverse elements. For example, disubstituted quinazolines were constructed starting from compound 1 (4,6-dichloroquinazoline) using a nucleophilic substitution reaction to install a particular aniline to the C4 position followed by a Suzuki coupling reaction to install an aromatic side chain to the C6 position of the quinazoline (Scheme 1 ).
2. Rationally designed focused library synthesis was accomplished using the synthetic scheme exemplifi ed in Scheme 2 ( 17 ) . Compound 4 ( Ethyl-4,6-dichloroquinoline-3-carboxylate) was subjected to nucleophilic addition by particular aryl anilines to afford compound 5 (Scheme 2 ). Lithium aluminum hydride (LAH)-mediated reduction of the ethyl ester furnished the corresponding benzyl alcohol compound 6 . Benzylic oxidation with MnO 2 followed by Horner-Emmons-Wardsworth olefination generated the cyclized compound 7 . Finally, a Suzuki coupling reaction was used to install an additional aryl side chain at C6 position of the quinoline.
Chemical Synthesis Methodology
A detailed synthetic protocol is provided below:
(a) To a solution of compound 4 (1 equiv.) in 1,4-dioxane was added aniline (1-2 equiv.) at room temperature. The reaction mixture was then heated to 100°C for 4-6 h and then allowed to cool to room temperature. An aqueous NaOH (1N) solution was added to neutralize the reaction mixture. The resultant solution was diluted with water and extracted with ethyl acetate. After the removal of the solvents under vacuum, the residue was purifi ed by fl ash column chromatography (hexanes/EtOAc) to afford compound 5 ( see Note 1 ).
(b) To a solution of compound 5 (1 equiv.) in THF at 0°C was added LAH (3-5 equiv.) dropwise. After 15-20 min, the solution was warmed to room temperature and stirred for 1-4 h before carefully quenching with methanol and water. Dilution of the mixture with EtOAc and fi ltration through celite furnished crude 6 , which was used in the next step without further purifi cation ( see Note 2 ).
(c) To a solution of compound 6 in CH 2 Cl 2 (1 equiv.) at room temperature was added MnO 2 (10 equiv. mass). After 1-4 h, the reaction mixture was fi ltered through celite. The fi ltrate was concentrated and placed in a sealed tube and dissolved in dry EtOH. K 2 CO 3 (3 equiv.) and triethyl phosphonoacetate were then added sequentially. The resulting mixture was heated to 100°C for 12-16 h before cooling to room temperature. Upon removal of the solvents under vacuum, the residue was diluted with water followed by extraction with ethyl acetate (3× (d) To a solution of compound 7 in 1,4-dioxane at room temperature was added subsequently PdCl 2 (Ph 3 P) 2 (0.1 equiv.), t -Bu-Xphos (0.1 equiv.), Na 2 CO 3 (3 equiv., 1N) and boronic acids or pinacol boronic esters. After degassing, the resultant mixture was heated to 100°C for 6 h before cooling to room temperature and fi ltering through celite. Upon removal of the solvents, the residue was subjected to column chromatography purifi cation (hexanes/EtOAc) to furnish the desired compounds as exemplifi ed by compound 8 ( see Note 4 ). The structure of Torin1 generated following above procedures was shown in Fig. 3 .
1. HEK-293T cells that stably expressed N-terminally FLAGtagged raptor using vesicular stomatitis virus G-pseudotyped MSCV retrovirus was used as a source of mTORC1 complex.
2. The HEK293T cells were lysed in 50 mM HEPES, pH 7.4, 150 mM NaCl, and 0.4% CHAPS at 4°C for 30 min, and the insoluble fraction was removed by centrifugation at 39,000 G for 30 min. Supernatants were incubated with FLAG-M2 monoclonal antibody-conjugated agarose for 1 h and then washed with two column volumes of wash buffer 1 (50 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM DTT and 2 mM ATP, and 0.1% CHAPS) and another two column volumes of wash buffer 2 (50 mM HEPES, pH 7.4, 200 mM NaCl, and 0.1% CHAPS).
3. mTORC1 complex was eluted with 100 μ g/ml 3× FLAG peptide in 50 mM HEPES, pH 7.4, 500 mM NaCl, and 0.1% CHAPS, then concentrated by centrifugation. Pure mTORC1 was isolated after gel fi ltration using a tandem Superose 6 10/300 GL column (GE Healthcare) in 50 mM HEPES, pH 7.4 and 150 mM NaCl on an AKTA purifi er (GE Healthcare).
1. mTORC1 (0.1 μ g each) was incubated with serially diluted inhibitors (threefold, 11 points) for 30 min in 5 μ l kinase buffer (25 mM HEPES, pH 7.4, 10 mM MgCl 2 , 4 mM MnCl 2 , 50 mM KCl) in a 384-well low volume plate (Corning). 
Biochemical Assay of mTORC1 Complex
The kinase reaction was initiated by the addition of an equal
volume of kinase buffer containing 0.8 μ M GFP-labeled 4E-BP1 and 100 μ M ATP at room temperature. After the kinase reaction for 1 h, the reaction was stopped by the addition of 10 μ l of solution containing 20 mM EDTA and 4 nM Tb-labeled antiphospho 4E-BP1 (T46) antibody (Invitrogen).
3. After incubation for 30 min, the FRET signal between Tb and GFP within the immune complex was read using Envision plate reader (PerkinElmer). Each data point was duplicated and IC 50 values were calculated using Prism4 software (GraphPad).
1. Cell Lysis: Cells were rinsed once with ice-cold PBS and lysed in an ice-cold lysis buffer (40 mM HEPES, pH 7.4, 2 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, and 0.3% CHAPS or 1% Triton X-100, and one tablet of EDTAfree protease inhibitors per 25 ml). The soluble fractions of cell lysates were isolated by centrifugation at 13,000 rpm for 10 min in a microcentrifuge ( 18 ) .
2. Cellular IC 50 values for mTOR were determined using p53
MEFs. Cells were treated with vehicle or increasing concentrations of compound for 1 h and then lysed. Phosphorylation of S6K1 Thr-389 was monitored by immunoblotting using a phospho-specifi c antibody.
3. Cellular IC 50 values for PI3K were determined using p53
−/− MEFs. Cells were treated with vehicle or increasing concentrations of compound for 1 h and then lysed. Phosphorylation of Akt Thr-308 was monitored by immunoblotting using a phospho-specifi c antibody. The summary of Torin1's biochemical and cellular IC 50 s was shown in Table 1 . An mTOR homology model was built with Modeller(9v6) based on a published PI3K γ crystal structure complexed with GDC-0941 (PDB: 3DBS). Compounds were docked into the model with Autodock Vina ( 19 ) . The presumed proper binding conformation was selected based on the binding modes of structurally related inhibitors whose co-structures had been determined crystallographically. An example of the docking result of Torin1 with mTOR complex was shown in Fig. 4 . 1. Ambit kinome wide selectivity profi le was performed in Ambit Bioscience with KinomeScan TM technology. Interesting compounds were profi led at a concentration of 10 μ M against a diverse panel of 442 kinases by Ambit Biosciences. Scores for primary screen hits are reported as a percent of the DMSO control (% control). For kinases where no score is shown, no measurable binding was detected. The lower the score, the lower the Kd is likely to be, such that scores of zero represent strong hits. Scores are related to the probability of a hit, but are not strictly an affi nity measurement. At a screening concentration of 10 μ M, a score of less than 10% implies that the false-positive probability is less than 20% and the Kd is most likely less than 1 μ M. A score between 1 and 10% implies that the false-positive probability is less than 10%, although it is impossible to assign a quantitative affi nity from a single-point primary screen. A score of less than 1% implies that the false-positive probability is less than 5% and the Kd is most likely less than 1 μ M.
Cellular Assays of mTOR and PI3K Activities
Molecular Modeling
Invitrogen lipid kinase panel profi le was conducted in
LifeScience Inc. using SelectScreen ® technology by testing IC 50 on individual kinase with ten testing points from a starting 1 μ M drug concentration. PIKK family kinase profi ling result of Torin1 in Ambit and Invitrogen was shown in Table 2 .
The study was performed in Sai Advantium Pharma Limited
Company (India) with male Swiss Albino mice following single intravenous bolus, oral administration, and intraperitoneal injection. 5. All samples were processed for analysis by precipitation using acetonitrile and analyzed with a partially validated LC/MS/ MS method (LLOQ -1.138 ng/ml). Pharmacokinetic parameters were calculated using the noncompartmental analysis tool of WinNonlin ® Enterprise software (version 5.2). The I.V., P.O., and I.P. studies of Torin1 were summarized in Table 3 . 1. Torin1 was formulated by dissolving the compound at a concentration of 25 mg/ml in 100% N -methyl-2-pyrrolidone followed by dilution (1:4) with sterile 50% PEG-400 prior to injection.
Ambit Kinome Wide and Invitrogen
2. Six-week-old male C57BL/6 mice were fasted overnight prior to drug treatment. The mice were treated with vehicle (for 10 h) or Torin1 (20 mg/kg for 2, 6, or 10 h) by IP injection, and then refed 1 h prior to sacrifi ce (CO 2 asphyxiation).
Pharmacodynamic Studies
3. Tissues were collected and frozen on dry ice. The frozen tissue was thawed on ice and lysed by sonication in tissue lysis buffer (50 mM HEPES, pH 7.4, 40 mM NaCl, 2 mM EDTA, 1.5 mM sodium orthovanadate, 50 mM sodium fl uoride, 10 mM sodium pyrophosphate, 10 mM sodium β -glycerophosphate, 0.1% SDS, 1.0% sodium deoxycholate, and 1.0% Triton, supplemented with protease inhibitor cocktail tablets [Roche]).
4. The concentration of clear lysate was measured using the Bradford assay and samples were subsequently normalized by protein content and analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. The result of PD study of Torin1 was exemplifi ed in Fig. 5 . 1. 2 × 10 6 U87MG glioblastoma cells were resuspended in 100 μ l of media that had been premixed with matrigel, and was injected subcutaneously in the upper fl ank region of mice (6 weeks old immunodefi cient) that had been anesthetized with isofl urane. Tumors were allowed to grow to 1 cm 3 in size ( see Note 6 ).
2. Animals were divided into two treatment groups randomly for vehicle and Torin1. Torin1 was formulated as 5 mg/ml in a solution of N -methyl-2-pyrrolidone:PEG400:water 3.9. Animal Xenograft Study (U87 Model) 1. Some series of compound 5 would require CHCl 3 /iPrOH (4:1) extraction system due to a poor solubility in EtOAC.
2. LAH should be added at 0°C to avoid facile over reduction of the benzyl alcohol to the toluene-like product. The reaction is typically monitored carefully by LC-MS to avoid over reduction after warming up to room temperature. A 0°C ice-water bath is preferred during the quenching procedure and the methanol should be added drop-wise due to the exothermic reaction. Extra EtOAc would be used to rinse the fi ltrate to avoid loss of the product in the celite.
3. Complete removal of the EtOH under vacuum is needed to avoid complications with the purifi cation process. 4. Some compound 8 analogs are very polar and require reverse phase column chromatography with MeOH/water or CH 3 CN/water solvent system.
Notes
5. All blood samples were collected in microcentrifuge tubes containing K2EDTA as an anticoagulant. At each time point, plasma samples from a set of three mice were separated by centrifugation and stored below −70°C until bioanalysis.
6. Immunodefi cient mice (NCR nude, nu/nu; Taconic Laboratories) were maintained in a pathogen-free facility and were given autoclaved food and water ad libitum. All animal studies were performed according to the offi cial guidelines from the MIT Committee on Animal Care and the American Association of Laboratory Animal Care.
